The FDA just granted “Breakthrough Therapy,” aka the use of magic mushrooms for treatment therapy in difficult cases. More specifically, the active psychedelic drug psilocybin is allowed for testing on patients. Which, just so happens to be the active substance in psychedelic mushrooms.
Scientists that regularly study psychedelic drugs are overjoyed with the news. Moving forward, the FDA will assist researchers to help develop drugs that can help treat depression and other serious conditions or diseases. Psilocybin could be the answer.
Roland Griffiths, Ph.D. and Professor of Psychiatry at Johns Hopkins University says this is a positive change.
“This is a significant positive development in the potential future regulatory approval of psilocybin, a classic psychedelic drug, for medicinal purposes. After a decades-long hiatus of research with psilocybin and related psychedelic drugs, investigators in the United States and Europe have demonstrated the safety and preliminary signs of efficacy of psilocybin for a variety of therapeutic applications.”
Just to be clear — “Breakthrough Therapy” doesn’t necessarily mean that the FDA will approve the widespread use of psilocybin. However, those with treatment-resistant depression and other ailments may be eligible for such treatment.
“Although the addiction liability of these drugs is low that doesn’t mean they’re safe, and they certainly need to be regulated in some fashion. FDA will ultimately be responsible for determining the parameters of that regulation.”
On the other hand, some believe psilocybin mushrooms may become legal in a few years.